Milestone Reached in BEST1 Gene Therapy Trial
According to GlobeNewswire, Opus Genetics has officially completed enrollment for Cohort 1 of its ongoing Phase 1/2 clinical study evaluating OPGx-BEST1, an investigational AAV-based gene therapy designed for patients with inherited retinal diseases (IRDs) linked to the BEST1 gene. For the inherited retinal disease community, the advancement of clinical trials representing potential targeted interventions offers hope for conditions that currently lack approved treatments.
Key Details of the OPGx-BEST1 Study
The adaptive, open-label Phase 1/2 trial is examining the safety and efficacy of a single-eye subretinal administration of OPGx-BEST1 in adult participants. The study includes individuals diagnosed with Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB). Enrollment for Cohort 1 reached a total of five participants, comprising three individuals with BVMD and two with ARB.
Opus Genetics reported that baseline demographics for the trial participants were shared during the ARVO Annual Meeting. For participants with the dominant form of BEST disease (BVMD), the company completed an additional in vitro platform step to verify that each participant's specific disease mutation is amenable to gene augmentation.
Potential Impact for Patients and Families
BEST1-related retinal degenerations affect thousands of individuals worldwide and are characterized by progressive vision loss. Because there are currently no approved treatments for these specific conditions, clinical trials like the OPGx-BEST1 study are closely watched by patients, families, and advocacy groups. The therapy utilizes a proprietary platform aimed at delivering a functional copy of the BEST1 gene directly to the retinal pigment epithelium (RPE) cells, targeting the root genetic cause of the disease.
Looking Ahead
Opus Genetics reported that it anticipates announcing three-month topline data from Cohort 1 in September 2026. Following this announcement, the company plans to present the findings at an upcoming ophthalmology medical conference later in the year.